InvestorsHub Logo
Followers 10
Posts 997
Boards Moderated 0
Alias Born 01/17/2005

Re: None

Thursday, 10/26/2017 1:13:11 PM

Thursday, October 26, 2017 1:13:11 PM

Post# of 2794
More from the PR

"These fifteen centers perform approximately a third of all AML related bone marrow transplants. Our ability to introduce Iomab-B in these centers bodes well for enrollment in the trial and also the commercial opportunity for Iomab-B as the top fifty centers account for approximately eighty percent of bone marrow transplants."
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ATNM News